James J. Harding, MD

Medical Oncologist | Clinical Investigator | Cancer Drug Developer | Associate Chair IRB | HPB Cancers | Phase 1 | MSKCC

[James J. Harding, MD @HardingJJMD]

Great to see this work out, Aruj Dhyani. Great to see #ADC target expression in #BTC, supports several ongoing clinical trials. @MSKCancerCenter @MSK_DeptOfMed
https://t.co/U6sZxGMXtc

[Angela Lamarca @DrAngelaLamarca]

An absolute honour @HardingJJMD 😊

🗞️Just published!
Our latest review on #targeted therapies in #BiliaryMalignancies in @JHepatology

https://t.co/79b17kczg0

[James J. Harding, MD @HardingJJMD]

@DrAngelaLamarca and Do Youn Oh!

@HardingJJMD enjoyed writing with you on #personalized #therapy #biliarytractcancers. Promise, limitations, and solutions!

@MSK_DeptOfMed @MSKCancerCenter @JHepatology

https://t.co/N2PWU1NrCC

[James J. Harding, MD @HardingJJMD]

@DrAngelaLamarca and Do Youn Oh!

@HardingJJMD enjoyed writing with you on #personalized #therapy #biliarytractcancers. Promise, limitations, and solutions!

@MSK_DeptOfMed @MSKCancerCenter @JHepatology

https://t.co/N2PWU1NrCC

[James J. Harding, MD @HardingJJMD]

Congratulations @CowzerDarren. Great deep dive #biliarytractcancer #genomics outcomes and resistance! @MSK_DeptOfMed @MSKCancerCenter @MskccCMO @DSolit @GABOUALFA @EileenMOReilly

[Clinical Cancer Research @CCR_AACR]

Now online: Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer https://t.co/9zzgMQIaif

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

New findings presented at #ASCO26 suggest a new approach could help slow the growth of intermediate-stage liver cancer.

An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa (@GABOUALFA) found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).

“By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.”

Learn more: https://t.co/iJZVsoaIS0

[James J. Harding, MD @HardingJJMD]

#ASCO2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #HER2 #RAS #BTC! Advanced Fellow Aruj Dhyani #YIA #ADC #BTC Assistant Attending @rohit_thum #MTAP #NET #BTC #PDAC. Glad to mentor, but grateful for what you teach me too!

[James J. Harding, MD @HardingJJMD]

@rohit_thum congratulations on this awesome poster #MTAP important target in #GI

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

#ASCO26 poster session with @rohit_thum, who shares his research about “Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers" with a fellow attendee. @ASCO

[James J. Harding, MD @HardingJJMD]

@OrlaFitz10 Great work! Critical foundational work for our ongoing #R01. @GABOUALFA @EileenMOReilly @YJanjigianMD.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK research fellow @OrlaFitz10 shared her poster "Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling" during #ASCO26. @ASCO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Proud to see 18 MSK staff recognized as 2026 Conquer Cancer Grants & Awards recipients ahead of #ASCO26. Congratulations to this outstanding group helping advance the future of cancer research and care. 👏

[James J. Harding, MD @HardingJJMD]

Looking forward to joining faculty of this year #cancer #phase1 #HPB @myESMO @MSKCancerCenter

[ESMO - Eur. Oncology @myESMO]

⏳ Still time to join #ESMOTATAsia26

Be part of ESMO Targeted Anticancer Therapies Asia 2026, a key Asia Pacific forum for cancer drug development.

👉 Register by 3 June and save: https://t.co/OdLFBU9KML

#ESMOMeetings

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer.

#Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030.

MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment.

“This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.”

Learn more about this research: https://t.co/eXzwBUekyq @AACR

[Rohit Thummalapalli @rohit_thum]

Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed

[Arndt Vogel @ArndtVogel]

🔥off the press: EMERALD-3 Phase III trial positive.
👉Significant PFS benefit for STRIDE/Lenva + TACE, trend of OS benefit
👉Trend for PFS benefit for STRIDE + TACE
���Looking forward to see more details
@myESMO @EASLedu @ILCAnews

[James J. Harding, MD @HardingJJMD]

Thank you @GABOUALFA, @MSK_DeptOfMed for many years of mentorship/support in #HPB cancers. Amazing to win this @theNCI #R01 award. @EileenMOReilly , @YJanjigianMD @DSolit @OlcaBasturk @MskccCMO @MSKBiostats @MSKCancerCenter

[Ghassan Abou-Alfa @GABOUALFA]

Congratulations @HardingJJMD on your #R01. @MSKCancerCenter @MSK_DeptOfMed and all colleagues are happy for you!

[Ghassan Abou-Alfa @GABOUALFA]

Congratulations @HardingJJMD on your #R01. @MSKCancerCenter @MSK_DeptOfMed and all colleagues are happy for you!

[Ghassan Abou-Alfa @GABOUALFA]

It was a great honor and delight for @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA and @HardingJJMD to join this superb teaching effort. Thanks @oncodaily for the opportunity

[James J. Harding, MD @HardingJJMD]

Great Ride for #Liver #bileduct #cancer! Thank Chris Crane and Matt McMillan for joining The LIVE Riders! @Cycle4Survival @MSK_DeptOfMed @MSKCancerCenter.

[James J. Harding, MD @HardingJJMD]

Great work @OrlaFitz10 Glad to mentor you and happy you are part of our #HPB team @MSKCancerCenter, @MSK_DeptOfMed Excellent editorial on #HER2 directed therapy in #biliarytractcancer. https://t.co/ePITSvg7K9

[James J. Harding, MD @HardingJJMD]

Support #Liver and #BileDuctCancer Research! We're participating in @Cycle4Survival to raise money for rare cancer research at @MSKCancerCenter, and your support would mean so much to us. Make a 100% tax-deductible donation using the link. Thank you! https://t.co/i2irFY24tT